27 Apr Fucidin 250 Mg Film-coated Tablets (Section 21 product)
| Company name &
Address |
Registration number | Batch number | Expiry date | Pack size | First distributed | Re-call Classification | Re-call Date |
| EQUITY PHARMACEUTICALS (PTY) LTD
Office 1; 100 Sovereign Drive Route 21 Nellmapius Drive |
Section 21 | C97098 | 01/2026 | 36 tablets | 30 August 2023 | Class II Type C | 14.August.2025 |
Reason for recall
This recall is initiated because Equity Pharmaceuticals (Pty) Ltd was informed by the manufacturer that the tablets are recalled due to out of specification results for impurities during routine stability testing. Therefore, this batch is being recalled.
Advice to HCPs/Distributors/Public
We request that you refrain from selling any of the affected batch of Fucidin 250 mg tablets and return them to us with immediate effect. We, Equity Pharmaceuticals, will collect all your stock which will be credited accordingly.
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points, and the recall process was started.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.